LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool

If your child has had an MRI in the past two months demonstrating white matter abnormalities, but has not yet received a diagnosis, they may be eligible to participate in a study investigating whole genome sequencing (WGS) as a first-line diagnostic tool.

In the LeukoSEQ study, a family with a newly identified leukodystrophy will submit blood samples and medical records for review to help doctors test new genetic technologies and help us understand how they may help in the leukodystrophies.

To learn more about this study, visit the clinical trial page or submit our Referral Survey and a LeukoSEQ study coordinator will contact you with additional information.